Dear Editor-in-Chief
In China, about 112 million people are chronically infected with the hepatitis B virus (HBV) (1) . HBV infection remains a common public health problem worldwide. Study showed that effective antiviral treatment could slow the progression of hepatitis B (2, 3). However, 60% of Chinese chronic hepatitis B patients who were candidates for antiviral treatment were not receiving antiviral treatment (4). Our previous study indicated that patients receiving antiviral treatment bore heavy economic burden. Health insurance can share economic risks. But beneficiaries of health insurance with low co-payments are likely to use more healthcare resources compared to those paying higher co-payments (5) . So the reasonable copayments for hepatitis B patients and their willing to pay were of great interest. Between August and December 2012, we conducted the survey of patients with HBV-related diseases in 3 county hospitals from 3 model regions in Jiangsu Province, China. 430 patients were observed and their attitude toward copayment was investigated. Among the patients 321 (74.7%) were males and 109 (25.3%) were females. 367（85.3%）were receiving antiviral treatment, and 63（14.7%）were not receiving antiviral treatment. In the study, among the five options, nearly 40% patients chose to co-pay 10%-19%. About 80% patients chose copayment lower than 40%, only 6% patients chose co-payment higher than 60%.Choice of the patient with different economic condition was statistically significant (P<0.05). There was no significant difference among variable in terms of sex, marital status, insurance type, receiving antiviral treatment or not. The results have some implication for public health policy-making. Strengthen health education to highlight the importance of antiviral treatment to effectively control spread of the virus. 
